Emmaus Life Sciences, Inc. (EMMA)
OTCMKTS · Delayed Price · Currency is USD
0.0089
0.00 (0.00%)
Apr 27, 2026, 9:30 AM EST
Emmaus Life Sciences Employees
As of December 31, 2025, Emmaus Life Sciences had 33 total employees, including 32 full-time and 1 part-time employees. The number of employees decreased by 2 or -5.71% compared to the previous year.
Employees
33
Change (1Y)
-2
Growth (1Y)
-5.71%
Revenue / Employee
$377,364
Profits / Employee
-$227,030
Market Cap
624.68K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 33 | -2 | -5.71% | 32 | 1 |
| Dec 31, 2024 | 35 | -20 | -36.36% | 34 | 1 |
| Dec 31, 2023 | 55 | 0 | - | 51 | 4 |
| Dec 31, 2022 | 55 | -7 | -11.29% | 54 | 1 |
| Dec 31, 2021 | 62 | 4 | 6.90% | 58 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Altamira Therapeutics | 11 |
| Eloxx Pharmaceuticals | 10 |
| Hepion Pharmaceuticals | 2 |
| Bio-Path Holdings | 1 |
| CNBX Pharmaceuticals | 1 |
Emmaus Life Sciences News
- 4 weeks ago - Emmaus Life Sciences Reports Annual Financial Results - Business Wire
- 4 months ago - Emmaus Life Sciences Announces Strategic Transaction - Business Wire
- 5 months ago - Emmaus Life Sciences Reports Quarterly Financial Results - PRNewsWire
- 10 months ago - Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements - PRNewsWire
- 1 year ago - Emmaus Life Sciences Reports Improved Quarterly Financial Results - PRNewsWire
- 1 year ago - Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer - PRNewsWire
- 1 year ago - Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program - PRNewsWire
- 1 year ago - Emmaus Life Sciences Reports 2023 Financial Results - PRNewsWire